High risk of leukemia after short-term dose-intensive chemotherapy in young patients with solid tumors Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Leukemia
  • Myelodysplastic Syndromes
  • Neoplasms
  • Neoplasms, Second Primary

abstract

  • Repetitive high-dose use of alkylating agents given with topoisomerase-II inhibitors is strongly leukemogenic, even with modest cumulative doses of each drug. This finding is notable for the following reasons: (1) it undermines predictions that limited use of high-dose chemotherapy might be minimally leukemogenic, and (2) it contrasts strikingly with the previously reported low risk of t-AML following treatment of pediatric solid tumors with chemotherapy lacking the alkylator dose-intensity and prominence of etoposide that are hallmarks of current regimens.

publication date

  • September 1998

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 9738570

Additional Document Info

start page

  • 3016

end page

  • 20

volume

  • 16

number

  • 9